Kruger EA - Search Results

1

Approaches to preclinical screening of antiangiogenic agents.

Kruger EA, Duray PH, Price DK, Pluda JM, Figg WD. Kruger EA, et al. Semin Oncol. 2001 Dec;28(6):570-6. doi: 10.1016/s0093-7754(01)90026-0. Semin Oncol. 2001. PMID: 11740811 Review.

2

Endostatin inhibits microvessel formation in the ex vivo rat aortic ring angiogenesis assay.

Kruger EA, Duray PH, Tsokos MG, Venzon DJ, Libutti SK, Dixon SC, Rudek MA, Pluda J, Allegra C, Figg WD. Kruger EA, et al. Biochem Biophys Res Commun. 2000 Feb 5;268(1):183-91. doi: 10.1006/bbrc.1999.2018. Biochem Biophys Res Commun. 2000. PMID: 10652234

3

Protein binding alters the activity of suramin, carboxyamidotriazole, and UCN-01 in an ex vivo rat aortic ring angiogenesis assay.

Krüger EA, Figg WD. Krüger EA, et al. Clin Cancer Res. 2001 Jul;7(7):1867-72. Clin Cancer Res. 2001. PMID: 11448898

4

A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer.

Figg WD, Arlen P, Gulley J, Fernandez P, Noone M, Fedenko K, Hamilton M, Parker C, Kruger EA, Pluda J, Dahut WL. Figg WD, et al. Among authors: kruger ea. Semin Oncol. 2001 Aug;28(4 Suppl 15):62-6. doi: 10.1016/s0093-7754(01)90157-5. Semin Oncol. 2001. PMID: 11685731 Clinical Trial.

5

5'-OH-thalidomide, a metabolite of thalidomide, inhibits angiogenesis.

Price DK, Ando Y, Kruger EA, Weiss M, Figg WD. Price DK, et al. Among authors: kruger ea. Ther Drug Monit. 2002 Feb;24(1):104-10. doi: 10.1097/00007691-200202000-00017. Ther Drug Monit. 2002. PMID: 11805730

6

Inhibition of angiogenesis: treatment options for patients with metastatic prostate cancer.

Figg WD, Kruger EA, Price DK, Kim S, Dahut WD. Figg WD, et al. Among authors: kruger ea. Invest New Drugs. 2002 May;20(2):183-94. doi: 10.1023/a:1015626410273. Invest New Drugs. 2002. PMID: 12099578 Review.

7

Antiangiogenic activity of N-substituted and tetrafluorinated thalidomide analogues.

Ng SS, Gütschow M, Weiss M, Hauschildt S, Teubert U, Hecker TK, Luzzio FA, Kruger EA, Eger K, Figg WD. Ng SS, et al. Among authors: kruger ea. Cancer Res. 2003 Jun 15;63(12):3189-94. Cancer Res. 2003. PMID: 12810647

8

Endothelial monocyte activating polypeptide II induces endothelial cell apoptosis and may inhibit tumor angiogenesis.

Berger AC, Alexander HR, Tang G, Wu PS, Hewitt SM, Turner E, Kruger E, Figg WD, Grove A, Kohn E, Stern D, Libutti SK. Berger AC, et al. Microvasc Res. 2000 Jul;60(1):70-80. doi: 10.1006/mvre.2000.2249. Microvasc Res. 2000. PMID: 10873516

9

Thalidomide up-regulates prostate-specific antigen secretion from LNCaP cells.

Dixon SC, Kruger EA, Bauer KS, Figg WD. Dixon SC, et al. Among authors: kruger ea. Cancer Chemother Pharmacol. 1999;43 Suppl:S78-84. doi: 10.1007/s002800051103. Cancer Chemother Pharmacol. 1999. PMID: 10357564

10

Carboxyamido-triazole inhibits angiogenesis by blocking the calcium-mediated nitric-oxide synthase-vascular endothelial growth factor pathway.

Bauer KS, Cude KJ, Dixon SC, Kruger EA, Figg WD. Bauer KS, et al. Among authors: kruger ea. J Pharmacol Exp Ther. 2000 Jan;292(1):31-7. J Pharmacol Exp Ther. 2000. PMID: 10604929

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

39 results

Search Page

Filters